We speculate that small-molecule inhibitors and/or antagonists targeting Ras and Raf-1 at domains and/or regions that are not required to form the Ku70-Ras-Raf signalosome might be beneficial in controlling the development and/or progression of cancers with hyperactivated Ras-ERK signaling. This evidence concerns the gene XRCC6 and cancer.